Cargando…

Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck

Introduction: Data regarding treatment and survival outcome of patients with adenocarcinoma of the head and neck are limited to case reports and case series. As a consequence of lacking evidence, treatment guidelines do not exist. We aimed to analyze the effect of a bimodal irradiation regime with i...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbaba, Sati, Mock, Andreas, Hoerner-Rieber, Juliane, Held, Thomas, Katayama, Sonja, Forster, Tobias, Freudlsperger, Christian, Rieken, Stefan, Herfarth, Klaus, Plinkert, Peter, Debus, Juergen, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705231/
https://www.ncbi.nlm.nih.gov/pubmed/31475108
http://dx.doi.org/10.3389/fonc.2019.00755
_version_ 1783445592650809344
author Akbaba, Sati
Mock, Andreas
Hoerner-Rieber, Juliane
Held, Thomas
Katayama, Sonja
Forster, Tobias
Freudlsperger, Christian
Rieken, Stefan
Herfarth, Klaus
Plinkert, Peter
Debus, Juergen
Adeberg, Sebastian
author_facet Akbaba, Sati
Mock, Andreas
Hoerner-Rieber, Juliane
Held, Thomas
Katayama, Sonja
Forster, Tobias
Freudlsperger, Christian
Rieken, Stefan
Herfarth, Klaus
Plinkert, Peter
Debus, Juergen
Adeberg, Sebastian
author_sort Akbaba, Sati
collection PubMed
description Introduction: Data regarding treatment and survival outcome of patients with adenocarcinoma of the head and neck are limited to case reports and case series. As a consequence of lacking evidence, treatment guidelines do not exist. We aimed to analyze the effect of a bimodal irradiation regime with intensity modulated radiotherapy (IMRT) and carbon ion boost on local control (LC) and survival in adenocarcinoma patients for a large patient collective. Materials and Methods: Patient records of eighty consecutive patients treated between 2009 and 2018 were analyzed retrospectively and Kaplan-Meier estimates for LC, overall survival (OS) and progression-free survival (PFS) were compared among patients with salivary gland adenocarcinoma (SGAC), salivary duct adenocarcinoma (SDAC), and intestinal-type adenocarcinoma (ITAC) according to the World Health Organization (WHO). Prognostic factors were identified using the log-rank test and cox-regression modeling. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). Results: Median follow-up was 41 months. The 3-year and estimated 5-year Kaplan-Meier rates for all patients were 83 and 75% for LC, 74 and 50% for OS and 60 and 53% for PFS, respectively. While bimodal RT for ITAC resulted in a significantly decreased 3-year LC rate of 50 vs. 93% for each SGAC and SDAC (p < 0.01), no statistical significant survival differences could be identified across the three groups regarding OS (p = 0.08) and PFS (p = 0.063). 3-year OS was 88% for SGAC, 78% for SDAC and 67% for ITAC and 3-year PFS was 72% for SGAC, 53% for SDAC and 44% for ITAC, respectively. Nevertheless, in subgroup analysis, OS for ITAC was significantly worse compared to SGAC (p = 0.024). In multivariate analysis, bilateral tumor side (vs. unilateral) solely could be identified as independent negative prognostic factor for LC (p < 0.01). Treatment was well-tolerated with 21% acute (n = 17) and 25% (n = 20) late grade ≥3 toxicities. Conclusion: Radiotherapy including active raster-scanning carbon ion boost for relatively radio resistant adenocarcinomas of the head and neck resulted in favorable survival outcome for salivary gland and salivary duct adenocarcinomas with moderate toxicity. However, local control and prognosis for bilateral intestinal-type adenocarcinomas (ITAC) seem to remain low even after dose-escalation.
format Online
Article
Text
id pubmed-6705231
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67052312019-08-30 Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck Akbaba, Sati Mock, Andreas Hoerner-Rieber, Juliane Held, Thomas Katayama, Sonja Forster, Tobias Freudlsperger, Christian Rieken, Stefan Herfarth, Klaus Plinkert, Peter Debus, Juergen Adeberg, Sebastian Front Oncol Oncology Introduction: Data regarding treatment and survival outcome of patients with adenocarcinoma of the head and neck are limited to case reports and case series. As a consequence of lacking evidence, treatment guidelines do not exist. We aimed to analyze the effect of a bimodal irradiation regime with intensity modulated radiotherapy (IMRT) and carbon ion boost on local control (LC) and survival in adenocarcinoma patients for a large patient collective. Materials and Methods: Patient records of eighty consecutive patients treated between 2009 and 2018 were analyzed retrospectively and Kaplan-Meier estimates for LC, overall survival (OS) and progression-free survival (PFS) were compared among patients with salivary gland adenocarcinoma (SGAC), salivary duct adenocarcinoma (SDAC), and intestinal-type adenocarcinoma (ITAC) according to the World Health Organization (WHO). Prognostic factors were identified using the log-rank test and cox-regression modeling. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). Results: Median follow-up was 41 months. The 3-year and estimated 5-year Kaplan-Meier rates for all patients were 83 and 75% for LC, 74 and 50% for OS and 60 and 53% for PFS, respectively. While bimodal RT for ITAC resulted in a significantly decreased 3-year LC rate of 50 vs. 93% for each SGAC and SDAC (p < 0.01), no statistical significant survival differences could be identified across the three groups regarding OS (p = 0.08) and PFS (p = 0.063). 3-year OS was 88% for SGAC, 78% for SDAC and 67% for ITAC and 3-year PFS was 72% for SGAC, 53% for SDAC and 44% for ITAC, respectively. Nevertheless, in subgroup analysis, OS for ITAC was significantly worse compared to SGAC (p = 0.024). In multivariate analysis, bilateral tumor side (vs. unilateral) solely could be identified as independent negative prognostic factor for LC (p < 0.01). Treatment was well-tolerated with 21% acute (n = 17) and 25% (n = 20) late grade ≥3 toxicities. Conclusion: Radiotherapy including active raster-scanning carbon ion boost for relatively radio resistant adenocarcinomas of the head and neck resulted in favorable survival outcome for salivary gland and salivary duct adenocarcinomas with moderate toxicity. However, local control and prognosis for bilateral intestinal-type adenocarcinomas (ITAC) seem to remain low even after dose-escalation. Frontiers Media S.A. 2019-08-13 /pmc/articles/PMC6705231/ /pubmed/31475108 http://dx.doi.org/10.3389/fonc.2019.00755 Text en Copyright © 2019 Akbaba, Mock, Hoerner-Rieber, Held, Katayama, Forster, Freudlsperger, Rieken, Herfarth, Plinkert, Debus and Adeberg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Akbaba, Sati
Mock, Andreas
Hoerner-Rieber, Juliane
Held, Thomas
Katayama, Sonja
Forster, Tobias
Freudlsperger, Christian
Rieken, Stefan
Herfarth, Klaus
Plinkert, Peter
Debus, Juergen
Adeberg, Sebastian
Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title_full Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title_fullStr Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title_full_unstemmed Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title_short Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
title_sort treatment outcome of a combined dose-escalated treatment regime with helical tomotherapy® and active raster-scanning carbon ion boost for adenocarcinomas of the head and neck
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705231/
https://www.ncbi.nlm.nih.gov/pubmed/31475108
http://dx.doi.org/10.3389/fonc.2019.00755
work_keys_str_mv AT akbabasati treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT mockandreas treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT hoernerrieberjuliane treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT heldthomas treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT katayamasonja treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT forstertobias treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT freudlspergerchristian treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT riekenstefan treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT herfarthklaus treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT plinkertpeter treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT debusjuergen treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck
AT adebergsebastian treatmentoutcomeofacombineddoseescalatedtreatmentregimewithhelicaltomotherapyandactiverasterscanningcarbonionboostforadenocarcinomasoftheheadandneck